Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
종목 코드 CDXS
회사 이름Codexis Inc
상장일Apr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
직원 수188
유형Ordinary Share
회계 연도 종료Apr 22
주소200 Penobscot Dr
도시REDWOOD CITY
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94063
전화16504218100
웹사이트https://www.codexis.com/
종목 코드 CDXS
상장일Apr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음